{"schema_version":"1.0","type":"article","title":"Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path?","url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.md","lang":"en","date":"2026-09-30","publish_at":"2026-09-30T08:00:00+08:00","updated_at":"2026-09-30","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["Novo Nordisk","Kallyope","肥胖症","GLP-1","非腸泌素","K-554"],"summary":"Why pursue non-incretin programs alongside an established GLP-1 franchise? K-554’s neural-circuit hypothesis, human evidence and usable dose range frame the relationship between efficacy, tolerability, persistence and product value.","key_points":[],"facts":[],"sections":["【01｜Eating Less and Eating Less Because of Discomfort Are Different Research Questions】","【02｜Three Programs Preserve Different Product-Format Options】","【03｜January’s Timeline Needs to Be Checked Against Later Evidence】","【04｜Eight Years of Collaboration Do Not Automatically Create One Asset History】","【05｜Better Tolerability Could First Change Who Can Stay on Treatment】","References"],"references":[{"title":"[1] [Jacob Petersen's public announcement]","source":"","date":"","url":"https://www.linkedin.com/posts/jacob-petersen-820529_im-excited-to-share-that-novo-nordisk-has-activity-7506720635704963073-rE3z/"},{"title":"[2] [Kallyope 2026 strategic priorities, January 7, 2026]","source":"","date":"","url":"https://kallyope.com/kallyope-announces-2026-strategic-priorities-for-migraine-and-metabolism-portfolio-based-on-novel-neural-circuits-platform/"},{"title":"[3] [Novo Nordisk–Kallyope research collaboration, June 19, 2018]","source":"","date":"","url":"https://www.globenewswire.com/news-release/2018/06/19/1600406/0/en/kallyope-and-novo-nordisk-announce-collaboration-to-discover-novel-therapeutics-for-obesity-and-diabetes.html"},{"title":"[4] [Kallyope licensing announcement, Business Wire republication, September 10, 2024]","source":"","date":"","url":"https://markets.financialcontent.com/wral/article/bizwire-2024-9-10-kallyope-announces-license-agreement-with-novo-nordisk"},{"title":"[5] [ClinicalTrials.gov K-554 search (no readable results obtained in this check)]","source":"","date":"","url":"https://clinicaltrials.gov/search?term=K-554&viewType=Card"},{"title":"[6] [Wegovy U.S. prescribing information, revised June 2026]","source":"","date":"","url":"https://www.novo-pi.com/wegovy.pdf"},{"title":"[7] [Nature: Dissociable hindbrain GLP1R circuits for satiety and aversion, July 10, 2024]","source":"","date":"","url":"https://www.nature.com/articles/s41586-024-07685-6"}],"images":[{"alt":"Gut signals connect to appetite regulation in the brain on the left; laboratory research and abstract candidate molecules appear on the right. Both connect to a document for more treatment options. Undisclosed targets and unproven human value are stated.","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs-en/FIG01_EN_v1.png"},{"alt":"Three independent rows show K-554 peptide and two small-molecule programs. Calendar, document and laboratory icons mark the weekly design, company IND-ready description, novel target and lead optimization. Undisclosed receptors or targets carry question marks.","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs-en/FIG02_EN_v1.png"},{"alt":"A central K-554 document labeled company description IND-ready branches by dotted lines to regulatory records, study participants, sampling and neutral records, and measurement with a calendar. No curve or numerical result is shown. Public confirmation remains necessary.","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs-en/FIG03_EN_v1.png"},{"alt":"A neutral human silhouette connects to a safety shield, tolerability and persistence records, measurement and time for efficacy and durability, and treatment paths for monotherapy or combination positioning. No before-and-after weight comparison, curve or success symbol is shown.","url":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs-en/FIG04_EN_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novo-kallyope-non-incretin-obesity-programs-en/FIG01_EN_v1.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-30）。Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path?。https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-30-novo-kallyope-non-incretin-obesity-programs.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}